January 23, 2015, NewBio Therapeutics announced today that NBT has successfully completed technology transfer of NBT 828 project to Genor Biopharma. One clinical candidate-NBT828 ADC-1 selected by Genor Pharma will go for further development for IND application in 2016. NBT828 project consists of a GB221 antibody that targets Her2 with cancer-cell killing agent attached using one of NBT’s proprietary linkers and conjugation technology. In preclinical testing, NBT828 ADCs demonstrated superior potent, targeted anticancer activity against Her2-expressing tumors.
January 23, 2015, NewBio Therapeutics announced today that NBT has successfully completed technology transfer of NBT 828 project to Genor Biopharma. One clinical candidate-NBT828 ADC-1 selected by Genor Pharma will go for further development for IND application in 2016. NBT828 project consists of a GB221 antibody that targets Her2 with cancer-cell killing agent attached using one of NBT’s proprietary linkers and conjugation technology. In preclinical testing, NBT828 ADCs demonstrated superior potent, targeted anticancer activity against Her2-expressing tumors.